TrialAmerican journal of kidney diseases : the official journal of the National Kidney Foundation2014

Rationale and design of the DIPAK 1 study: a randomized controlled clinical trial assessing the efficacy of lanreotide to Halt disease progression in autosomal dominant polycystic kidney disease.

Esther Meijer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.